Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3045% below fair value
$0.90−0.05 (-4.77%)
Close on Nov 17, 2026Market cap $52.49MP/E 22.5Yield –
Spero Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Spero Therapeutics's operating income for the twelve months ending Jun 30, 2026 was $6.03M. For fiscal 2025 it was $6.31M. The highest annual figure on record is $21.48M in fiscal 2023.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.31M | – |
| FY2024 | Dec 31, 2024 | -$73.36M | -441.5% |
| FY2023 | Dec 31, 2023 | $21.48M | – |
| FY2022 | Dec 31, 2022 | -$42.20M | – |
| FY2021 | Dec 31, 2021 | -$87.97M | – |
| FY2020 | Dec 31, 2020 | -$79.11M | – |
| FY2019 | Dec 31, 2019 | -$63.22M | – |
| FY2018 | Dec 31, 2018 | -$42.81M | – |
| FY2017 | Dec 31, 2017 | -$41.73M | – |
| FY2016 | Dec 31, 2016 | -$33.22M | – |
| FY2015 | Dec 31, 2015 | -$13.33M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.93M | – |
| Q1 FY2026 | Mar 31, 2026 | -$7.54M | – |
| Q4 FY2025 | Dec 31, 2025 | $31.41M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$2.44M | – |
| Q1 FY2025 | Mar 31, 2025 | -$14.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.73M | -143.0% |
| Q3 FY2024 | Sep 30, 2024 | -$18.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$19.06M | – |
| Q1 FY2024 | Mar 31, 2024 | -$13.98M | – |
| Q4 FY2023 | Dec 31, 2023 | $50.53M | +94.9% |
| Q3 FY2023 | Sep 30, 2023 | -$1.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$12.89M | – |
| Q1 FY2023 | Mar 31, 2023 | -$14.23M | – |
| Q4 FY2022 | Dec 31, 2022 | $25.92M | – |
| Q3 FY2022 | Sep 30, 2022 | -$11.83M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.08M | – |
| Q1 FY2022 | Mar 31, 2022 | -$30.21M | – |
| Q4 FY2021 | Dec 31, 2021 | -$27.50M | – |
| Q3 FY2021 | Sep 30, 2021 | -$22.52M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.54M | – |
| Q1 FY2021 | Mar 31, 2021 | -$19.40M | – |
| Q4 FY2020 | Dec 31, 2020 | -$18.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$19.02M | – |
| Q2 FY2020 | Jun 30, 2020 | -$18.48M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.82M | – |
| Q4 FY2019 | Dec 31, 2019 | -$25.88M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.99M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.65M | – |
| Q1 FY2019 | Mar 31, 2019 | -$5.70M | – |
| Q4 FY2018 | Dec 31, 2018 | -$11.08M | – |
| Q3 FY2018 | Sep 30, 2018 | -$10.94M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.97M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.82M | – |
| Q4 FY2017 | Dec 31, 2017 | -$14.00M | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.97M | – |
| Q2 FY2017 | Jun 30, 2017 | -$10.17M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.60M | – |
| Q4 FY2016 | Dec 31, 2016 | -$8.81M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.91M | – |
See a number that looks wrong?